Premium
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy
Author(s) -
Loke Justin,
Metzner Marlen,
Boucher Rebecca,
Jackson Aimee,
Hopkins Louise,
Pavlu Jiri,
Tholouli Eleni,
Drummond Mark,
Peniket Andy,
Bishop Rebecca,
Fox Sonia,
Vyas Paresh,
Craddock Charles
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17823
Subject(s) - azacitidine , medicine , romidepsin , myeloid leukaemia , chemotherapy , oncology , decitabine , myeloid leukemia , histone deacetylase , histone , gene expression , chemistry , dna methylation , gene , biochemistry
Summary Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro . The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m 2 on Days 8 and 15, with AZA 75 mg/m 2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance.